<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00408616</url>
  </required_header>
  <id_info>
    <org_study_id>GT-12</org_study_id>
    <nct_id>NCT00408616</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Grazax in Children</brief_title>
  <official_title>A Phase III Trial Investigating the Efficacy and Safety of Grazax in Children Aged 5-16 Years With Grass Pollen Induced Rhinoconjunctivitis With or Without Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ALK-Abelló A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ALK-Abelló A/S</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate if immunotherapy with Grazax is safe and reduces
      the hayfever symptoms and the use of symptom relieving medications in children during the
      grass pollen season
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2006</start_date>
  <completion_date type="Actual">November 2007</completion_date>
  <primary_completion_date type="Actual">September 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hayfever symptoms</measure>
    <time_frame>Grass pollen season 2007</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Intake of hayfever symptom relieving medication</measure>
    <time_frame>Grass pollen season 2007</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Combined hayfever symptom and medication scores</measure>
    <time_frame>Grass pollen season 2007</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Asthma symptoms and medication</measure>
    <time_frame>Grass pollen season 2007</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global Evaluation of treatment efficacy</measure>
    <time_frame>Grass pollen season 2007</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacoeconomic Assessment</measure>
    <time_frame>9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunological Assessment</measure>
    <time_frame>9 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">253</enrollment>
  <condition>Allergy</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Grazax treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Grazax Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Grazax-R</intervention_name>
    <description>Grass tablet, 75.000 SQ per day for one year</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Grazax Placebo</intervention_name>
    <description>Grazax Placebo, 0 SQ tablet per day for one year</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Boys and girls 5-16 years of age

          -  A clinical history of grass pollen induced hayfever

          -  Positive Skin Prick Test to Phleum pratense

          -  Positive specific IgE against Phleum pratense

        Exclusion Criteria:

          -  History of seasonal hayfever symptoms (and/or asthma) caused by another allergen than
             Phleum pratense during or overlapping the grass pollen season

          -  History of perennial hayfever (and/or asthma) that needs medication due to an allergen
             to which the child is regularly exposed

          -  History of severe asthma

          -  Current severe atopic dermatitis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>16 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Friedrich Kaiser, Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tangstedter Landstrasse 77, 22415 Hamburg, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tangstedter Landstrasse 77</name>
      <address>
        <city>Hamburg</city>
        <zip>22415</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <results_reference>
    <citation>Bufe A, Eberle P, Franke-Beckmann E, Funck J, Kimmig M, Klimek L, Knecht R, Stephan V, Tholstrup B, Weisshaar C, Kaiser F. Safety and efficacy in children of an SQ-standardized grass allergen tablet for sublingual immunotherapy. J Allergy Clin Immunol. 2009 Jan;123(1):167-173.e7. doi: 10.1016/j.jaci.2008.10.044.</citation>
    <PMID>19130937</PMID>
  </results_reference>
  <verification_date>March 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 6, 2006</study_first_submitted>
  <study_first_submitted_qc>December 6, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 7, 2006</study_first_posted>
  <last_update_submitted>March 6, 2009</last_update_submitted>
  <last_update_submitted_qc>March 6, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 9, 2009</last_update_posted>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

